论文部分内容阅读
目的检测细胞外基质金属蛋白酶诱导剂(EMMPRIN)在胰腺癌中的表达及其与P-糖蛋白(P-gp)、血管内皮生长因子(VEGF)的关系,以探讨胰腺癌细胞多药耐药和浸润转移是否有关联。方法应用免疫组化SP法检测34例胰腺癌患者癌组织中EMMPRIN、P-gp和VEGF的表达,用卡方检验和相关分析了解其与临床病理参数的关系。结果EMMPRIN、P-gp和VEGF在胰腺癌组织中阳性表达率分别为61．8％、55．9％和64．7％。EMMPRIN、P-gp、VEGF阳性表达与性别、年龄、肿瘤大小及病理分化程度无关(P＞0．05),但与淋巴结转移有关(P＜0．05)。EMMPRIN表达与P-gp、VEGF分别相关(r=0．398和r=0．432,P＜0．05)。结论胰腺癌中EMMPRIN与P-gp、VEGF表达有关,提示肿瘤耐药、浸润和转移之间有一定相关性,EMMPRIN可能是其中的关键因子。
Objective To detect the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) in pancreatic carcinoma and its relationship with P-glycoprotein (P-gp) and vascular endothelial growth factor (VEGF) in pancreatic cancer cells And infiltration of metastasis is related. Methods Immunohistochemical SP method was used to detect the expression of EMMPRIN, P-gp and VEGF in 34 cases of pancreatic cancer, and their relationship with clinicopathological parameters was analyzed by chi-square test and correlation analysis. Results The positive rates of EMMPRIN, P-gp and VEGF in pancreatic cancer tissues were 61.8%, 55.9% and 64.7%, respectively. The positive expression of EMMPRIN, P-gp and VEGF was not related to gender, age, tumor size and pathological differentiation (P> 0.05), but correlated with lymph node metastasis (P <0.05). EMMPRIN expression was correlated with P-gp and VEGF (r = 0.398 and r = 0.432, P <0.05). Conclusion EMMPRIN is associated with the expression of P-gp and VEGF in pancreatic cancer, suggesting that there is a certain correlation between EMMPRIN and drug resistance, invasion and metastasis. EMMPRIN may be one of the key factors.